HRP20170805T1 - Pripravak za kontinuiranu primjenu inhibiotra dopa dekarboksilaze - Google Patents

Pripravak za kontinuiranu primjenu inhibiotra dopa dekarboksilaze Download PDF

Info

Publication number
HRP20170805T1
HRP20170805T1 HRP20170805TT HRP20170805T HRP20170805T1 HR P20170805 T1 HRP20170805 T1 HR P20170805T1 HR P20170805T T HRP20170805T T HR P20170805TT HR P20170805 T HRP20170805 T HR P20170805T HR P20170805 T1 HRP20170805 T1 HR P20170805T1
Authority
HR
Croatia
Prior art keywords
preparation
pharmaceutically acceptable
levodopa
kit according
liquid composition
Prior art date
Application number
HRP20170805TT
Other languages
English (en)
Croatian (hr)
Inventor
Oron Yacoby-Zeevi
Mara Nemas
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42320738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170805(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of HRP20170805T1 publication Critical patent/HRP20170805T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
    • C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C243/18—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20170805TT 2009-05-19 2010-05-17 Pripravak za kontinuiranu primjenu inhibiotra dopa dekarboksilaze HRP20170805T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17951109P 2009-05-19 2009-05-19
PCT/IL2010/000400 WO2010134074A1 (en) 2009-05-19 2010-05-17 Compositions for continuous administration of dopa decarboxylase inhibitors
EP10725880.8A EP2432454B1 (en) 2009-05-19 2010-05-17 Compositions for continuous administration of dopa decarboxylase inhibitors

Publications (1)

Publication Number Publication Date
HRP20170805T1 true HRP20170805T1 (hr) 2017-08-25

Family

ID=42320738

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20170805TT HRP20170805T1 (hr) 2009-05-19 2010-05-17 Pripravak za kontinuiranu primjenu inhibiotra dopa dekarboksilaze
HRP20202038TT HRP20202038T1 (hr) 2009-05-19 2020-12-21 Pripravci namijenjeni kontinuiranoj primjeni inhibitora dopa-dekarboksilaze

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20202038TT HRP20202038T1 (hr) 2009-05-19 2020-12-21 Pripravci namijenjeni kontinuiranoj primjeni inhibitora dopa-dekarboksilaze

Country Status (26)

Country Link
US (9) US8193243B2 (enExample)
EP (3) EP3777839A1 (enExample)
JP (3) JP5643297B2 (enExample)
KR (2) KR101709904B1 (enExample)
CN (2) CN102438587B (enExample)
AR (3) AR078413A1 (enExample)
AU (1) AU2010250766B2 (enExample)
BR (1) BRPI1011031B8 (enExample)
CA (1) CA2761624C (enExample)
CL (1) CL2011002895A1 (enExample)
CY (1) CY1119495T1 (enExample)
DK (2) DK3192500T3 (enExample)
ES (2) ES2840748T3 (enExample)
HR (2) HRP20170805T1 (enExample)
HU (2) HUE052685T2 (enExample)
IL (1) IL216383A (enExample)
LT (1) LT2432454T (enExample)
MX (2) MX364974B (enExample)
NZ (1) NZ596963A (enExample)
PL (2) PL2432454T3 (enExample)
PT (2) PT2432454T (enExample)
RU (3) RU2559083C9 (enExample)
SG (3) SG10201505101VA (enExample)
SI (1) SI2432454T1 (enExample)
WO (1) WO2010134074A1 (enExample)
ZA (1) ZA201109037B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN192600B (enExample) * 1996-10-18 2004-05-08 Hoechst Celanese Corp
EP3777839A1 (en) 2009-05-19 2021-02-17 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
NZ610911A (en) * 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
EP2854764B1 (en) 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CN103845318A (zh) * 2012-12-07 2014-06-11 天津市汉康医药生物技术有限公司 恩他卡朋分散片
US20160022573A1 (en) * 2013-03-13 2016-01-28 Neuroderm, Ltd. Method for treatment of parkinson's disease
JP6538063B2 (ja) * 2013-11-05 2019-07-03 シンアジャル コーポレイション 口を介する連続的薬物送達のためのデバイスおよび方法
EP3777833B1 (en) * 2014-03-13 2023-10-18 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
CN107072973A (zh) 2014-09-04 2017-08-18 劳波索尔制药有限公司 含左旋多巴、多巴胺脱羧酶抑制剂和comt抑制剂的药物组合物及其施用方法
CA2965379A1 (en) 2014-10-21 2016-04-28 Abbvie Inc. Carbidopa and l-dopa prodrugs and methods of use
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
KR20180004756A (ko) 2015-05-06 2018-01-12 신애질 코포레이션 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
AU2016358511A1 (en) 2015-11-24 2018-06-21 Neuroderm Ltd. Pharmaceutical compositions comprising levodopa amide and uses thereof
MY190011A (en) * 2016-04-11 2022-03-22 Univ Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
US10064834B2 (en) 2016-05-09 2018-09-04 Texas Tech University System Carbidopa for the treatment of cancer
IL271169B (en) 2017-06-05 2022-09-01 Dizlin Pharmaceuticals Ab An infusion of levodopa
US20230123806A1 (en) * 2017-07-07 2023-04-20 Neuroderm, Ltd. Device for subcutaneous delivery of fluid medicament
CA3095341A1 (en) * 2018-03-29 2019-10-03 Avion Pharmaceuticals, Llc Levodopa fractionated dose composition and use
AU2019379806B2 (en) 2018-11-15 2025-08-14 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
WO2020252257A1 (en) * 2019-06-12 2020-12-17 President And Fellows Of Harvard College Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
US20230181508A1 (en) * 2020-08-31 2023-06-15 Purdue Pharma L.P. Compositions and methods for levodopa delivery
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
WO2022140448A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
EP4460289A4 (en) * 2022-01-03 2025-09-03 Neuroderm Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US3936495A (en) * 1973-11-27 1976-02-03 Merck & Co., Inc. Purification process
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4241082A (en) 1977-09-02 1980-12-23 Sankyo Company Limited Agents for promoting reproductive ability of domestic animals
JPS5450700A (en) 1977-09-28 1979-04-20 Sankyo Co Glazing agent of animal leather
JPS6021570B2 (ja) * 1978-07-04 1985-05-28 三共株式会社 ド−パ類の高濃度製剤の製法
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
DE252290T1 (de) * 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4684666A (en) * 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
WO1992007561A1 (en) * 1990-10-30 1992-05-14 Ss Pharmaceutical Co., Ltd. Antiphlogistic and analgesic gel preparation
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
GB9523833D0 (en) 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6245917B1 (en) * 1998-03-20 2001-06-12 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US7201923B1 (en) * 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
CN1303991C (zh) 1998-05-15 2007-03-14 沃尼尔·朗伯公司 γ－氨基丁酸衍生物的稳定药物制剂和其制备方法
US6274168B1 (en) * 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU3490300A (en) 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US7479498B2 (en) * 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US6348965B1 (en) * 1999-09-24 2002-02-19 Henry Palladino Solid state fluorescence and absorption spectroscopy
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
GB0017387D0 (en) * 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction
WO2003050261A2 (en) 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
WO2003084514A1 (en) * 2002-04-11 2003-10-16 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of carbidopa and levodopa
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
BR0315221A (pt) 2002-10-10 2005-08-23 Morphochem Ag Komb Chemie Compostos com atividade antibacteriana
JP2007531701A (ja) * 2003-07-18 2007-11-08 バクスター・インターナショナル・インコーポレイテッド 制御された相分離により調製される小球状粒子の作製方法、使用および組成物
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
ATE495739T1 (de) * 2003-08-29 2011-02-15 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
US20050053669A1 (en) 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
CN1901881A (zh) * 2003-10-31 2007-01-24 阿尔扎公司 用于增强的吸收的组合物和剂型
US20050163849A1 (en) * 2003-10-31 2005-07-28 Wong Patrick S. Compositions and dosage forms for enhanced absorption of iron
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
WO2006043532A1 (ja) * 2004-10-19 2006-04-27 Ono Pharmaceutical Co., Ltd. パーキンソン病治療剤
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101636145B (zh) 2006-05-31 2014-04-23 雅培产品有限公司 长期24小时经肠给予左旋多巴/卡比多巴
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
CA2682888A1 (en) * 2007-04-06 2008-10-16 Transform Pharmaceuticals, Inc. Systems and methods for delivering a fluid drug
CN101669925B (zh) 2008-09-10 2011-08-10 天津药物研究院 干粉吸入剂、其制备方法和用途
EP3777839A1 (en) 2009-05-19 2021-02-17 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
KR101187064B1 (ko) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
TR201808178T4 (tr) 2010-11-15 2018-07-23 Neuroderm Ltd Aktif ajanların transdermal dağıtımı için bileşimler.
NZ610911A (en) 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
BR112013014304A2 (pt) 2010-12-10 2016-07-19 Synagile Corp composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
US20160022573A1 (en) 2013-03-13 2016-01-28 Neuroderm, Ltd. Method for treatment of parkinson's disease
EP3777833B1 (en) 2014-03-13 2023-10-18 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
ES2627655T3 (es) 2017-07-31
US9101663B2 (en) 2015-08-11
EP2432454A1 (en) 2012-03-28
CY1119495T1 (el) 2018-03-07
JP2016121199A (ja) 2016-07-07
SG10201505101VA (en) 2015-07-30
NZ596963A (en) 2014-01-31
KR20160091424A (ko) 2016-08-02
US20100298428A1 (en) 2010-11-25
MX364974B (es) 2019-05-16
SI2432454T1 (sl) 2017-09-29
AU2010250766B2 (en) 2015-04-09
US9993451B2 (en) 2018-06-12
KR101641401B1 (ko) 2016-07-20
CN104546700A (zh) 2015-04-29
US20210077442A1 (en) 2021-03-18
AR078413A1 (es) 2011-11-09
BRPI1011031A2 (pt) 2016-08-16
PL2432454T3 (pl) 2017-10-31
EP3777839A1 (en) 2021-02-17
RU2559083C9 (ru) 2016-01-20
DK2432454T3 (en) 2017-06-19
US20190125708A1 (en) 2019-05-02
KR20120027371A (ko) 2012-03-21
US20160151317A1 (en) 2016-06-02
IL216383A0 (en) 2012-01-31
JP2015017144A (ja) 2015-01-29
JP5643297B2 (ja) 2014-12-17
HRP20202038T1 (hr) 2021-03-05
RU2678839C2 (ru) 2019-02-04
RU2011149976A (ru) 2013-06-27
JP2012527447A (ja) 2012-11-08
CN102438587B (zh) 2015-08-19
SG176159A1 (en) 2011-12-29
ZA201109037B (en) 2013-02-27
US9040589B2 (en) 2015-05-26
RU2015115064A (ru) 2015-11-20
US20140249231A1 (en) 2014-09-04
AU2010250766A1 (en) 2012-01-12
BRPI1011031B1 (pt) 2020-06-23
ES2840748T3 (es) 2021-07-07
LT2432454T (lt) 2017-07-10
MX2011012315A (es) 2011-12-16
SG10201709016RA (en) 2017-11-29
EP3192500B1 (en) 2020-12-02
EP3192500A1 (en) 2017-07-19
AR117502A2 (es) 2021-08-11
US20100298429A1 (en) 2010-11-25
CA2761624C (en) 2016-10-18
CL2011002895A1 (es) 2012-10-12
US20140249230A1 (en) 2014-09-04
EP2432454B1 (en) 2017-03-01
HUE052685T2 (hu) 2021-05-28
US9040590B2 (en) 2015-05-26
US8193243B2 (en) 2012-06-05
JP5921002B2 (ja) 2016-05-24
KR101709904B1 (ko) 2017-02-23
PT2432454T (pt) 2017-06-12
US7863336B2 (en) 2011-01-04
HUE033388T2 (en) 2017-12-28
JP6157678B2 (ja) 2017-07-05
RU2019101159A (ru) 2020-07-16
CN104546700B (zh) 2017-06-06
IL216383A (en) 2016-02-29
US20110269833A1 (en) 2011-11-03
CN102438587A (zh) 2012-05-02
DK3192500T3 (da) 2020-12-21
US20230321019A1 (en) 2023-10-12
WO2010134074A1 (en) 2010-11-25
AR117412A2 (es) 2021-08-04
PT3192500T (pt) 2021-01-05
BRPI1011031B8 (pt) 2021-05-25
PL3192500T3 (pl) 2021-04-06
CA2761624A1 (en) 2010-11-25
RU2559083C2 (ru) 2015-08-10

Similar Documents

Publication Publication Date Title
HRP20170805T1 (hr) Pripravak za kontinuiranu primjenu inhibiotra dopa dekarboksilaze
JP2012527447A5 (enExample)
CY1120005T1 (el) Συνεχης χορηγηση αναστολεων l-ντοπα, αποκαρβοξυλασης ντοπα, αναστολεων κατεχολ-ο-μεθυλ τρανσφερασης και συνθεσεις αυτων
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
PH12015501421A1 (en) Long-acting formulations of insulin
MX349383B (es) Formulaciones para el tratamiento de diabetes.
HRP20211442T1 (hr) Kombinacija za liječenje parkinsonove bolesti
HRP20140634T1 (hr) Farmaceutske otopine, postupak priprave i terapeutske upotrebe
GB2459809A (en) Fatty acid formulations and methods of use thereof
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
JP2016512230A5 (enExample)
WO2013116753A8 (en) Fatty acids as anti-inflammatory agents
BR112013028365A2 (pt) &#34;composição líquida compreendendo adi, composto compreendendo adi ligada covalentemente através de grupo de ligação a polietilenoglicol e uso de adi no preparo de composição para tratamento de câncer&#34;.
JP2015510888A5 (enExample)
WO2011097273A8 (en) Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine
ES2445846R1 (es) Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos
WO2011134979A3 (en) Stable aqueous mia/cd-rap formulations
MX2017000764A (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
BR112015017040A2 (pt) aumento de volume muscular em um ser humano com o uso de ácido hialurônico
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
HRP20230062T1 (hr) Formulacije buprenorfina sa produženim oslobađanjem
RU2575796C1 (ru) Пегилированный конъюгат варианта рекомбинантного консенсусного интерферона и способ его получения, и применение
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
BR112013031496A2 (pt) composição de aminoácidos
IT1392084B1 (it) Composizione immuno-nutrizionale